Proinflammatory cytokines and sepsis syndrome: Not enough, or too much of a good thing?

Trends in Immunology

Volumn 24, Issue 5, 2003, Pages 254-258

  Netea, Mihai G ^a   Van Der Meer, Jos W M ^a   Van Deuren, Marcel ^a   Kullberg, Bart Jan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; ETANERCEPT; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1BETA; LYMPHOTOXIN; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

BACTERIAL GROWTH; CAUSE OF DEATH; CLINICAL FEATURE; CYTOKINE RELEASE; DISEASE COURSE; DISEASE SEVERITY; FATALITY; HOST; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFECTION; INFECTION RISK; INFECTION SENSITIVITY; MICROBIAL ACTIVITY; MICROBIAL POPULATION DYNAMICS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN DEFICIENCY; PROTEIN FUNCTION; RECURRENT DISEASE; REVIEW; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

EID: 0038062839     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(03)00079-6     Document Type: Review

References (50)

1. van der Poll T., Lowry S.F. Tumor necrosis factor and sepsis: mediator of multiple organ failure or essential part of host defense? Shock. 3:1995;1-12.
2. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood. 87:1996;2095-2147.
3. Cohen J. The immunopathogenesis of sepsis. Nature. 420:2002;885-891.
4. Beutler B., et al. Passive immunization against cachexin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 229:1985;869-871.
5. Tracey K.J., et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 330:1987;662-664.
6. Mira J.-P., et al. Association of TNF2, a TNFα promoter polymorphism, with septic shock susceptibility and mortality. JAMA. 282:1999;561-568.
7. Weissensteiner T., Lanchbury J.S. TNFB polymorphisms characterize three lineages of TNF region microsatellite haplotypes. Immunogenetics. 47:1997;6-16.
8. Fischer C.J. Jr, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit. Care Med. 21:1993;318-327.
9. Abraham E., et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis syndrome. JAMA. 273:1995;934-941.
10. Fischer C.J., et al. Treatment of septic shock with the tumor necrosis factor:Fc fusion protein. New Engl. J. Med. 334:1996;1697-1702.
11. Bone R.C. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit. Care Med. 24:1996;1125-1128.
12. Westendorp R.G.J., et al. Release of tumor necrosis factor: an innate host characteristic that may contribute to the outcome of meningococcal disease. J. Infect. Dis. 171:1995;1057-1060.
13. Westendorp R.G.J., et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 349:1997;170-173.
14. Van Dissel J.T., et al. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet. 351:1998;950-953.
15. Waage A., et al. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J. Exp. Med. 169:1989;333-338.
16. Cannon J.G., et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J. Infect. Dis. 161:1990;79-84.
17. Tang G.-J., et al. Tumor necrosis factor gene polymorphysm and septic shock in surgical infection. Crit. Care Med. 28:2000;2733-2736.
18. Stuber, F. et al. ((1995) -1996) -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J. Inflamm. 46, 42-50.
19. Nakane A., et al. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect. Immun. 56:1988;2563-2569.
20. Echtenacher B., et al. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J. Immunol. 145:1990;3762-3766.
21. Netea M.G., et al. The increased susceptibility of TNFαLTα double knock-out mice to systemic candidiasis is due to defective recruitment and phagocytosis by neutrophils. J. Immunol. 163:1999;1498-1505.
22. Kullberg B.J., Van 't Wout J.W. Cytokines in the treatment of fungal infections. Biotherapy. 7:1994;195-210.
23. Polk H.C., et al. A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients. Am. J. Surg. 163:1992;191-196.
24. Van der Meer J.W.M. Defects in host defense mechanisms. Rubin R.H., Young L.S. Clinical Approach to Infection in the Compromised Host. 1994;33-66 Plenum.
25. Huang S., et al. Immune response in mice that lack the interferon-γ receptor. Science. 259:1993;1742-1745.
26. Vilcek J., et al. Knock-Outs of Interferons, Interferon Receptors and Interferons Signaling Components. 1998;Humana Press Inc.
27. Casanova J.L., Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol. 20:2002;581-620.
28. Nacy C.A., et al. Tumor necrosis factor-alpha: central regulatory cytokine in the induction of macrophage antimicrobial activities. Pathobiology. 59:1991;182-184.
29. Kindler V., et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell. 56:1989;731-740.
30. Hultgren O.H., et al. Critical role of signaling through IL-1 receptor for development of arthritis and sepsis during Staphylococcus aureus infection. J. Immunol. 168:2002;5207-5212.
31. Sahoo S., et al. Tumor necrosis factor gene polymorphisms correlate with infections after renal transplantation. Transplantation. 69:2000;880-884.
32. Freeman R.B.J., et al. Tumor necrosis factor gene polymorphisms correlate with infections after liver transplantation. Transplantation. 67:1999;1005-1010.
33. Arbour N.C., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 25:2000;187-191.
34. Lorenz E., et al. Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock. Arch. Intern. Med. 162:2002;1028-1032.
35. Gallin J.I. Interferon-gamma in the management of chronic granulomatous disease. Rev. Infect. Dis. 13:1991;973-978.
36. Arana B.A., et al. Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-γ in treating cutaneous leishmaniasis in Guatemala. Clin. Infect. Dis. 18:1994;381-384.
37. Gallin J.I., et al. Interferon-γ in the management of infectious diseases. Ann. Intern. Med. 123:1995;216-222.
38. Borges W.G., et al. Defective interleukin-12/interferon-γ pathway in patients with hyperimmunoglobulinemia E syndrome. J. Pediatr. 136:2000;176-180.
39. Netea M.G., et al. Th1/Th2 dysbalance in a family with hyper IgE syndrome. Neth. J. Med. 60:2002;349-354.
40. Lilic D., Gravenor I. Immunology of chronic mucocutaneous candidiasis. J. Clin. Pathol. 54:2001;81-83.
41. Ohno Y., et al. In vitro production of interleukin-1, interleukin-6, and tumor necrosis factor-α in insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 77:1993;1072-1077.
42. Taylor S.C., et al. Interferon production in sickle cell disease. Lymphokine Res. 9:1990;415-423.
43. Tsai C.Y., et al. Decreased IL-12 production by polymorphonuclear leukocytes in patients with active systemic lupus erythematosus. Immunol. Invest. 31:2002;177-189.
44. Barnes P.J. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin. Sci. 94:1998;557-572.
45. Granelli-Piperno A., et al. Stimulation of lymphokine release from T lymphoblasts, requirements for mRNA synthesis and inhibition by cyclosporin A. J. Exp. Med. 160:1984;1792-1802.
46. Keane J., et al. Tuberculosis associated with infliximab, a tumor necrossi factor α-neutralizing agent. New Engl. J. Med. 345:2001;1098-1104.
47. Antonaci S., et al. Monocyte- and cytokine-mediated effects on T immunoregulatory activity in the elderly. Cytobios. 58:1989;155-164.
48. Rytel M.W., et al. Interferon response to mitogens and viral antigens in elderly and young subjects. J. Infect. Dis. 153:1986;984-987.
49. Rink L., Kirchner H. Zinc-altered immune function and cytokine production. J. Nutr. 130:2000;1407S-1411S.
50. Netea, M.G. et al. Proinflammatory cytokines and the pathogenesis of sepsis. New Engl. J. Med. (in press).